Generic Name: eculizumab
Brand Name: Soliris
Manufacturer: Alexion Pharma Canada Corp.
Indications: Neuromyelitis optica spectrum disorder
Manufacturer Requested Reimbursement Criteria1: For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Submission Type: New Indication
Project Status: Pending
Call For Patient Input: January 24, 2020
Patient Input Closed: March 16, 2020
Anticipated Date: February 24, 2020
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.